AQST (Aquestive Therapeutics, Inc. Common Stock) Stock Analysis - News
Aquestive Therapeutics, Inc. Common Stock (AQST) is a publicly traded Healthcare sector company. As of May 21, 2026, AQST trades at $4.15 with a market cap of $518.74M and a P/E ratio of -6.70. AQST moved +2.20% today. Year to date, AQST is -33.07%; over the trailing twelve months it is +74.48%. Its 52-week range spans $2.12 to $7.55. Analyst consensus is strong buy with an average price target of $8.75. Rallies surfaces AQST's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in AQST news today?
Aquestive Therapeutics Q1 Revenues Up 66%, Net Loss Narrows to $8.1M: Aquestive Therapeutics posted a 66% revenue increase in Q1 2026 driven by higher license and royalty revenues, while net loss narrowed to $8.1 million. FDA human factors review and reimbursement challenges leave Anaphylm’s approval timeline uncertain, though company targets Canada, UK and EU filings without extra clinical studies.
Aquestive Therapeutics Q1 Revenues Up 66%, Net Loss Narrows to $8.1M: Aquestive Therapeutics posted a 66% revenue increase in Q1 2026 driven by higher license and royalty revenues, while net loss narrowed to $8.1 million. FDA human factors review and reimbursement challenges leave Anaphylm’s approval timeline uncertain, though company targets Canada, UK and EU filings without extra clinical studies.
Does Rallies summarize AQST news?
Yes. Rallies summarizes AQST news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is AQST research on Rallies investment advice?
No. Rallies provides research, data, and educational context for AQST. It does not provide personalized investment advice.
